Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company’s lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz). Furthermore, the Company’s pipeline includes biosimilar candidates to Lucentis® and Neulasta®.
The information on this website, including any investor downloads, is not an offer to sell or solicitation of an offer to buy any interest in the company. Any offer of solicitation will be made only by means of a confidential private offering memorandum or registration statement relating to any such interest in the company and solely in those jurisdictions where permitted by law. We ask that you review our “Legal Notice” section of the website, which includes important information you should consider prior to accessing these investor downloads. Downloading these files constitutes your acceptance and understanding of our Legal Notice. The Legal Notice includes important information relating to, among other things, use of and reliance upon the content of this website, our use of forward looking information and other important disclaimers. Please contact us prior to downloading if you have any questions.